2. Search Result
Search Result
Results for "

in

" in MedChemExpress (MCE) Product Catalog:

8081

Inhibitors & Agonists

13

Fluorescent Dye

40

Biochemical Assay Reagents

38

Peptides

5

Inhibitory Antibodies

67

Natural
Products

50

Recombinant Proteins

55

Isotope-Labeled Compounds

54

Antibodies

63

Click Chemistry

13

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-18758
    IN-1130
    1 Publications Verification

    		 TGF-β Receptor Inflammation/Immunology Cancer
    IN-1130 is a highly selective transforming growth factor-β type I receptor kinase (ALK5) inhibitor with an IC50 of 5.3 nM for ALK5-mediated Smad3 phosphorylation. IN-1130 inhibits ALK5 phosphorylation of casein (IC50=36 nM) and p38α mitogen-activated protein kinase (IC50=4.3 μM). IN-1130 suppresses renal fibrosis in obstructive nephropathy and blocks breast cancer lung metastasis .
    IN-1130
  • HY-161945
    IN-RNA-IN-2

    		HIV HIV Integrase Infection
    IN-RNA-IN-2 (compound 1a) is an inhibitor (IC50=70 nM) of the interaction between HIV-1 integrase and the viral RNA genome. IN-RNA-IN-2 exerts its anti-HIV activity by inhibiting the viral replication process .
    IN-RNA-IN-2
  • HY-P991494
    IN-002

    		RSV Infection
    IN-002 is a human monoclonal antibody (mAb) targeting F, Fusion glycoprotein F0. IN-002 can be used in respiratory syncytial virus (RSV) infections research.
    IN-002
  • HY-160678
    InhA-IN-7

    		Bacterial Infection
    InhA-IN-7 (Compound 11) is a Triclocan (HY-B1119) derivative with inhibitory activity towards enoyl-acyl carrier protein reductase (InhA) with an IC50 of 96 nM. InhA-IN-7 inhibits proliferations of Mycobacterium tuberculosis wildtype and mutant strains with MICs ranging from 19 to 75 μM .
    InhA-IN-7
  • HY-169104
    InhA-IN-8

    		Bacterial Infection
    InhA-IN-8 (compound 6c) is an orally active inhibitor of Mycobacterium tuberculosis InhA (enoyl ACP reductase). InhA-IN-8 has good inhibitory activity against Mtb UalRv (MIC = 0.5-1 μg/mL). InhA-IN-8 can be used in research on acute tuberculosis model mice .
    InhA-IN-8
  • HY-130119
    Integrin-IN-2

    		Integrin Cancer
    Integrin-IN-2 (compound 39) is an orally bioavailable pan αv integrin inhibitor. Integrin-IN-2 can increases the αvβ6, αvβ3, αvβ5 and αvβ8 binding affinities with pIC50 values of 7.8, 8.4, 8.4 and 7.4, respectively .
    Integrin-IN-2
  • HY-150588
    InhA-IN-3

    		Bacterial Infection
    InhA-IN-3 (Compound TU12) is a Mycobacterium tuberculosis InhA (an enoyl ACP-reductase) inhibitor with an IC50 of 17.7 μM .
    InhA-IN-3
  • HY-120884
    InhA-IN-5

    		Bacterial Infection
    InhA-IN-5 (compound 1) is a potent Mycobacterial tuberculosis (Mtb) trans-2-enoyl-acyl carrier protein reductase (InhA) inhibitor .
    InhA-IN-5
  • HY-173410
    iNOs-IN-6

    		NF-κB p38 MAPK NO Synthase Interleukin Related Inflammation/Immunology
    iNOs-IN-6 is an anti-inflammatory agent. iNOs-IN-6 inhibits NF-κB, iNOS, and MAPK expression(IC50: 0.2-0.62 μM). iNOs-IN-6 reduces IL-6, TNF-α, and IL-1β pro-inflammatory mediators levels (IC50: 0.4-0.69 μM) .
    iNOs-IN-6
  • HY-150055
    iNOs-IN-3

    		NO Synthase Inflammation/Immunology
    iNOs-IN-3 (Compound 2d) is an orally active nitric oxide synthase (iNOS) inhibitor (IC50=3.342 µM). iNOs-IN-3 shows anti-inflammatory activity and can be used in LPS-induced acute lung injury (ALI) research .
    iNOs-IN-3
  • HY-146309
    iNOS-IN-2

    		NO Synthase Inflammation/Immunology
    iNOS-IN-2 (Compound 53) is a potent down-regulator of inducible nitric oxide synthase (iNOS) protein. iNOS-IN-2 effectively inhibits the NO production (IC50=6.4 μM). iNOS-IN-2 has a potential therapeutic effect on chronic inflammation .
    iNOS-IN-2
  • HY-150589
    InhA-IN-4

    		Bacterial Infection
    InhA-IN-4 (TU14) is a Mycobacterium tuberculosis InhA (an enoyl ACP-reductase) inhibitor with an IC50 of 15.6 μM .
    InhA-IN-4
  • HY-160648
    InhA-IN-6

    		Bacterial Infection
    InhA-IN-6 (compound 8) is InhA inhibitor with the IC50 of 90 nM .
    InhA-IN-6
  • HY-168946
    InhA-IN-9

    		Bacterial Infection
    InhA-IN-9 (compound 7h) is a Mycobacterium tuberculosis InhA (an enoyl ACP-reductase) inhibitor. InhA-IN-9 could bind to InhA. InhA-IN-9 shows a antituberculosis activity at MIC value of 2 μg/mL .
    InhA-IN-9
  • HY-P10150
    IN-2-LF

    		Bacterial Infection
    IN-2-LF is an inhibitor of lethal factor. IN-2-LF also inhibits furin with an IC50 of 2 μM. IN-2-LF enhances protection against anthrax lethal toxin when in combination with D6R .
    IN-2-LF
  • HY-145846
    iNOs-IN-1
    1 Publications Verification

    		 NO Synthase Interleukin Related Inflammation/Immunology
    iNOs-IN-1 (YPW) is a potent inducible nitric oxide synthase (iNOS) inhibitor. iNOs-IN-1 can significantly inhibit the expression of IL-6 and iNOS, as well as reduce LPS-induced NO generation with dose-dependent manner in mouse macrophages. Anti-inflammatory effects .
    iNOs-IN-1
  • HY-168096
    iNOs-IN-5

    		NO Synthase Apoptosis Cardiovascular Disease Neurological Disease
    iNOs-IN-5 (Compound BN-4) is an inhibitor for iNOS with an IC50 of 0.1707 μM, and reduces NO levels in LPS (HT-D1056)-induced RAW264.7 cells. iNOs-IN-5 reduces the hypoxic injury stimulated ROS and lactate dehydrogenase expression, and exhibits anti-necrosis and anti-apoptosis efficacy. iNOs-IN-5 exhibits anti-cerebral ischemia and neuroprotective activities in SD rat models. iNOs-IN-5 is blood-brain barrier penetrable .
    iNOs-IN-5
  • HY-18758R
    IN-1130 (Standard)

    		TGF-β Receptor Inflammation/Immunology Cancer
    IN-1130 (Standard) is the analytical standard of IN-1130. This product is intended for research and analytical applications. IN-1130 is a highly selective transforming growth factor-β type I receptor kinase (ALK5) inhibitor with an IC50 of 5.3 nM for ALK5-mediated Smad3 phosphorylation. IN-1130 inhibits ALK5 phosphorylation of casein (IC50=36 nM) and p38α mitogen-activated protein kinase (IC50=4.3 μM). IN-1130 suppresses renal fibrosis in obstructive nephropathy and blocks breast cancer lung metastasis .
    IN-1130 (Standard)
  • HY-147047
    InhA-IN-2

    		Bacterial Infection
    InhA-IN-2 (Compound 23) is a Mycobacterium tuberculosis InhA (an enoyl ACP-reductase) inhibitor with an IC50 of 0.31 μM .
    InhA-IN-2
  • HY-146147
    Influenza virus-IN-5

    		Influenza Virus Infection
    Influenza virus-IN-5 (Compound 5f) is an inhibitor of influenza virus hemagglutinin (HA) with an EC50 of 1 nM against influenza A/H3N2 virus .
    Influenza virus-IN-5
  • HY-143493
    Influenza virus-IN-2

    		Influenza Virus Inflammation/Immunology
    Influenza virus-IN-2 (compound 19) is a potent influenza virus inhibitor with an EC50 of 2.58 µM and CC50 of 150.85 µM. Influenza virus-IN-2 shows a concentration dependent inhibition activity for PAN endonuclease with EC50 of 489.39 nM. Influenza virus-IN-2 shows shows anti-influenza A virus activities .
    Influenza virus-IN-2
  • HY-153570
    Influenza virus-IN-7

    		Influenza Virus Infection
    Influenza virus-IN-7 (Example 16) is an orally active cap-dependent endonuclease inhibitor that can be used for the research of influenza viral infectious diseases .
    Influenza virus-IN-7
  • HY-173204
    Influenza virus-IN-9

    		Influenza Virus Infection Inflammation/Immunology
    Influenza virus-IN-9 (12) is an influenza endonuclease inhibitor, with an IC50 of 0.03 μM .
    Influenza virus-IN-9
  • HY-143492
    Influenza virus-IN-1

    		Influenza Virus Inflammation/Immunology
    Influenza virus-IN-1 (compound 14) is a potent influenza A virus inhibitor with an EC50 of 2.46 µM and CC50 of >200 µM. Influenza virus-IN-1 shows a concentration dependent inhibition activity for PAN endonuclease with EC50 of 312.36 nM. Influenza virus-IN-1 shows shows anti-influenza A virus activities .
    Influenza virus-IN-1
  • HY-162805
    iNOS/TopoI-IN-1

    		NO Synthase Topoisomerase Apoptosis NF-κB Inflammation/Immunology Cancer
    iNOS/TopoI-IN-1 (compound AuL9) is a multi-target hybrid molecule with anti-tumor, anti-inflammatory and antioxidant activities. iNOS/TopoI-IN-1 inhibits the growth of breast cancer cells MCF-7 and MDA MB-231 in vitro with IC50 of 3.5 μM and 6.3 μM, respectively, and induces DNA damage and apoptosis of breast cancer cells by inhibiting human topoisomerase I (TopoI) (Ki=2.72 μM). In addition, NOS/TopoI-IN-1 inhibits the expression of iNOS by inhibiting the activation of NF-kB (Ki=1.49 μM) .
    iNOS/TopoI-IN-1
  • HY-146001
    Influenza virus-IN-4

    		Influenza Virus Inflammation/Immunology
    Influenza virus-IN-4 (compound 11e) is a potent influenza virus neuraminidase inhibitor with IC50s of 3.4, 0.094, 0.79, 0.077 µM for H5N1, H5N2, H5N6, H5N8, respectively. Influenza virus-IN-4 shows NA (neuraminidase enzyme)-inhibitory activity. Influenza virus-IN-4 shows low cytotoxicity with an CC50 of >200 µM. Influenza virus-IN-4 shows no obvious toxicity at the dose of 1500 mg/kg in mice .
    Influenza virus-IN-4
  • HY-155476
    Influenza virus-IN-8

    		Influenza Virus Infection
    Influenza virus-IN-8 (compound A4) is an inhibitor of influenza virus (Influenza Virus) that induces viral nucleoprotein (NP) aggregation and prevents its nuclear accumulation. Influenza virus-IN-8 has broad-spectrum anti-influenza activity and can inhibit the replication and transcription of influenza A virus. Influenza virus-IN-8 also inhibits Oseltamivir (HY-13317)-resistant H1N1/pdm09 strains .
    Influenza virus-IN-8
  • HY-146000
    Influenza virus-IN-3

    		Influenza Virus Inflammation/Immunology
    Influenza virus-IN-3 (compound 9) is a potent and selective influenza virus inhibitor with IC50s of 0.88, 0.10, 5.5, 0.51 µM for H5N1, H5N2, H5N6, H5N8, respectively. Influenza virus-IN-3 shows antiviral and NA (neuraminidase enzyme)-inhibitory activity. Influenza virus-IN-3 shows low cytotoxicity with an CC50 of >200 µM .
    Influenza virus-IN-3
  • HY-152078
    Influenza virus-IN-6

    		Influenza Virus Infection
    Influenza virus-IN-6 (Compound 35) is a potent influenza N-terminal domain of the polymerase acidic protein subunit (PAN) endonuclease inhibitor with an IC50 of 0.20 μM .
    Influenza virus-IN-6
  • HY-122844B
    Ifebemtinib tosylate

    BI-853520 tosylate; in-10018 tosylate

    		 FAK Cancer
    Ifebemtinib (tosylate) (BI-853520 (tosylate); IN-10018 (tosylate)) is a highly selective PTK2 kinase inhibitor. Ifebemtinib (tosylate) demonstrates anti-tumor activity. Ifebemtinib (tosylate) inhibits FAK autophosphorylation in prostate carcinoma cells. Ifebemtinib (tosylate) can inhibit spheroid formation and orthotopic tumor growth in vivo. Ifebemtinib (tosylate) can be studied in anticancer research such as solid tumors, breast cancer, and malignant pleural mesothelioma .
    Ifebemtinib tosylate
  • HY-122844
    Ifebemtinib
    1 Publications Verification

    BI-853520; in-10018

    		 FAK Cancer
    Ifebemtinib (BI 853520) is an orally active and potent focal adhesion kinase (FAK) inhibitor (recombinant FAK IC50=1 nM). Ifebemtinib shows anti-proliferative activity against cancer cells. Ifebemtinib inhibits FER Kinase and FES Kinase with IC50s of 900 nM and 1040 nM, respectively .
    Ifebemtinib
  • HY-146004
    Influenza A virus-IN-4

    		Influenza Virus Infection
    Influenza A virus-IN-4 (compound 23b), an Oseltamivir derivative, is a potent inhibitor of neuraminidase. Influenza A virus-IN-4 exerts powerful inhibitions on influenza viruses .
    Influenza A virus-IN-4
  • HY-161513
    iNOS/COX-2-IN-1

    		COX NO Synthase Inflammation/Immunology
    iNOS/COX-2-IN-1 (Compound 12e) is an inhibitor of cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS). iNOS/COX-2-IN-1 inhibits the NF-κB and MAPKs signaling pathways and thus exerts anti-inflammatory effects .
    iNOS/COX-2-IN-1
  • HY-159564
    iNOS/COX-2-IN-3

    		COX NO Synthase Inflammation/Immunology
    iNOS/COX-2-IN-3 (compound 7d) is a dual inhibitor of iNOS and COX-2, with potential anti-inflammatory activity against LPS (HY-D1056)-induced RAW 264.7 cells (IC50=3.48 μM). iNOS/COX-2-IN-3 has good plasma stability, oral activity and gastric safety, and its inhibitory activity on iNOS and COX-2 expression is 5.43-fold and 2.37-fold that of Indomethacin (HY-14397), respectively .
    iNOS/COX-2-IN-3
  • HY-108420
    INK4C-IN-2
    1 Publications Verification

    		 CDK Cancer
    INK4C-IN-2 (Compound 40) is the inhibitor for INK4C (also known as p18) and the activator for CDK4/6. INK4C-IN-2 increases the number and expansion capacity of mouse and human hematopoietic stem cells (HSCs) with EC50 of 5.21 nM, promotes the self-renewal and multilineage differentiation of HSCs. INK4C-IN-2 improves the expansion and long-term hematopoietic reconstruction ability of HSCs in mouse bone marrow transplantation model .
    INK4C-IN-2
  • HY-162492
    Influenza A virus-IN-14

    		Influenza Virus Infection
    Influenza A virus-IN-14 (Compound 37) is an inhibitor for influenza virus type A (IAV), which inhibits H1N1 with an EC50 of 23 nM. Influenza A virus-IN-14 exhibits low cytotoxicity with CC50 of more than 100 μM. Influenza A virus-IN-14 inhibits cytopathic effect and improves the survival rates of cell Calu3. Influenza A virus-IN-14 exhibits synergistic activity with the neuraminidase inhibitor Oseltamivir (HY-13317). Influenza A virus-IN-14 exhibits poor pharmacokinetic properties in CD-1 mouse .
    Influenza A virus-IN-14
  • HY-170646
    Influenza A virus-IN-15

    		Influenza Virus Infection
    Influenza A virus-IN-15 (Compound 9b), a quinoline derivative, is a broad-spectrum inhibitor of influenza A viruses with acceptable cytotoxicity (IC50: 0.88-6.33 μM). Influenza A virus-IN-15 can inhibit the transcription and replication of viral RNA and is used in research for its antiviral effects against influenza A viruses (IAV) .
    Influenza A virus-IN-15
  • HY-172913
    Influenza A virus-IN-16

    		Influenza Virus Infection
    Influenza A virus-IN-16 (compound 10) is a potent anti-viral agent. Influenza A virus-IN-16 inhibits pseudotyped H7N1 with an EC50 of 0.09 μM .
    Influenza A virus-IN-16
  • HY-131179
    Influenza A virus-IN-1

    		Influenza Virus Infection
    Influenza A virus-IN-1 is a dihydropyrrolidones derivative and is a potent inhibitor against wide subtypes of influenza A virus (IAV) with IC50 values from 3.11 μM to 7.13 μM. Influenza A virus-IN-1 efficiently inhibits replication of IAV, up-regulates the expression of key antiviral cytokines IFN-β and antiviral protein MxA .
    Influenza A virus-IN-1
  • HY-146167
    iNOS/PGE2-IN-1

    		NO Synthase Inflammation/Immunology
    iNOS/PGE2-IN-1 (compound 4a), an iNOS/PGE2 inhibitor, is a potent anti-inflammatory agent. iNOS/PGE2-IN-1 can inhibit LPS-induced NO production. iNOS/PGE2-IN-1 possesses low ulcerogenic liabilities .
    iNOS/PGE2-IN-1
  • HY-122844A
    Ifebemtinib hydrochloride

    BI-853520 hydrochloride; in-10018 hydrochloride

    		 FAK Cancer
    Ifebemtinib (BI-853520) hydrochloride is an orally active and potent focal adhesion kinase (FAK) inhibitor (IC50 = 1 nM for recombinant FAK). Ifebemtinib hydrochloride exhibits antiproliferative activity against cancer cells .
    Ifebemtinib hydrochloride
  • HY-149034
    Influenza A virus-IN-8

    S5

    		 Influenza Virus Infection Cancer
    Influenza A virus-IN-8 (S5) is a macrocyclic peptide with no cytotoxic. Influenza A virus-IN-8 is also a potent Influenza A Virus (IAV) inhibitor (with sufficient protease stability) with IC50s of 6.7 and 6.6 nM for H1 and H5 variants, respectively. Influenza A virus-IN-8 shows good affinitiescan to H1 variants, binds to a conserved region in the HA stem with a Kd of 1.0 nM .
    Influenza A virus-IN-8
  • HY-171204
    In vivo Jun Mouse Pre-designed siRNA-3

    		Small Interfering RNA (siRNA) Cancer
    In vivo Jun Mouse Pre-designed siRNA-3 is a siRNA product designed for the Jun (Mouse) gene and can be used for in vivo experiments in mice.
    In vivo Jun Mouse Pre-designed siRNA-3
  • HY-171202
    In vivo Jun Mouse Pre-designed siRNA-1

    		Small Interfering RNA (siRNA) Cancer
    In vivo Jun Mouse Pre-designed siRNA-1 is a siRNA product designed for the Jun (Mouse) gene and can be used for in vivo experiments in mice.
    In vivo Jun Mouse Pre-designed siRNA-1
  • HY-171203
    In vivo Jun Mouse Pre-designed siRNA-2

    		Small Interfering RNA (siRNA) Cancer
    In vivo Jun Mouse Pre-designed siRNA-2 is a siRNA product designed for the Jun (Mouse) gene and can be used for in vivo experiments in mice.
    In vivo Jun Mouse Pre-designed siRNA-2
  • HY-171206
    In vivo Jund Mouse Pre-designed siRNA-2

    		Small Interfering RNA (siRNA) Cancer
    In vivo Jund Mouse Pre-designed siRNA-2 is a siRNA product designed for the Jund (Mouse) gene and can be used for in vivo experiments in mice.
    In vivo Jund Mouse Pre-designed siRNA-2
  • HY-171201
    In vivo Igkc Mouse Pre-designed siRNA-3

    		Small Interfering RNA (siRNA) Inflammation/Immunology
    In vivo Igkc Mouse Pre-designed siRNA-3 is a siRNA product designed for the Igkc (Mouse) gene and can be used for in vivo experiments in mice.
    In vivo Igkc Mouse Pre-designed siRNA-3
  • HY-171207
    In vivo Jund Mouse Pre-designed siRNA-3

    		Small Interfering RNA (siRNA) Cancer
    In vivo Jund Mouse Pre-designed siRNA-3 is a siRNA product designed for the Jund (Mouse) gene and can be used for in vivo experiments in mice.
    In vivo Jund Mouse Pre-designed siRNA-3
  • HY-171205
    In vivo Jund Mouse Pre-designed siRNA-1

    		Small Interfering RNA (siRNA) Cancer
    In vivo Jund Mouse Pre-designed siRNA-1 is a siRNA product designed for the Jund (Mouse) gene and can be used for in vivo experiments in mice.
    In vivo Jund Mouse Pre-designed siRNA-1
  • HY-171200
    In vivo Igkc Mouse Pre-designed siRNA-2

    		Small Interfering RNA (siRNA) Inflammation/Immunology
    In vivo Igkc Mouse Pre-designed siRNA-2 is a siRNA product designed for the Igkc (Mouse) gene and can be used for in vivo experiments in mice.
    In vivo Igkc Mouse Pre-designed siRNA-2

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: